"Boronic Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
| Descriptor ID |
D001897
|
| MeSH Number(s) |
D01.029.260.110 D01.132.285 D02.203.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Boronic Acids".
Below are MeSH descriptors whose meaning is more specific than "Boronic Acids".
This graph shows the total number of publications written about "Boronic Acids" by people in this website by year, and whether "Boronic Acids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 1 | 3 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 5 | 6 |
| 2024 | 0 | 1 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Boronic Acids" by people in Profiles.
-
Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing Klebsiella pneumoniae in the hollow fiber infection model. Antimicrob Agents Chemother. 2026 04; 70(4):e0136525.
-
Polymeric Prodrugs using Dynamic Covalent Chemistry for Prolonged Local Anesthesia. Angew Chem Int Ed Engl. 2024 07 29; 63(31):e202406158.
-
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases. Am J Hematol. 2015 Aug; 90(8):E146-8.
-
Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun; 90(6):E122-3.
-
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. Br J Haematol. 2015 Jul; 170(1):118-22.
-
Proteomic profiling of na?ve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. Br J Haematol. 2015 Jul; 170(1):66-79.
-
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015 May; 169(3):352-5.
-
A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol. 2015 Apr; 169(1):36-43.
-
Biology, prognosis, and therapy of Waldenstr?m Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
-
Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 2014 Nov; 21(11):472-482.